Cargando…

Development and Validation of a Diagnostic Nomogram for Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Pneumonia Patients Undergoing Oral Glucocorticoid Treatment

PURPOSE: Pneumocystis jirovecii pneumonia (PJP) is an opportunistic but potentially fatal infection with increasing prevalence in HIV-free patients. Glucocorticoid therapy is one of the most important risk factors for PJP. The delay in diagnosis contributes to poor outcomes. Hence, the aim of this s...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Qin, Li, Lijuan, Zhang, Yue, He, Xing, Liu, Yafeng, Liu, Zhen, Yan, Haiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907006/
https://www.ncbi.nlm.nih.gov/pubmed/36760781
http://dx.doi.org/10.2147/IDR.S398850
_version_ 1784884083806961664
author Lang, Qin
Li, Lijuan
Zhang, Yue
He, Xing
Liu, Yafeng
Liu, Zhen
Yan, Haiying
author_facet Lang, Qin
Li, Lijuan
Zhang, Yue
He, Xing
Liu, Yafeng
Liu, Zhen
Yan, Haiying
author_sort Lang, Qin
collection PubMed
description PURPOSE: Pneumocystis jirovecii pneumonia (PJP) is an opportunistic but potentially fatal infection with increasing prevalence in HIV-free patients. Glucocorticoid therapy is one of the most important risk factors for PJP. The delay in diagnosis contributes to poor outcomes. Hence, the aim of this study was to develop and validate a nomogram for the diagnosis of PJP in patients with non-HIV-infected pneumonia who are undergoing oral glucocorticoid treatment. PATIENTS AND METHODS: This study was a retrospective, cross-sectional research. The development group included 434 patients who were admitted with pneumonia from 6 hospitals. Demographics, symptomatic features, laboratory and computed tomography data were analyzed using the least absolute shrinkage and selection operator (LASSO) to select potential diagnostic indicators. Binary logistic regression was used to develop a diagnostic nomogram. Another 119 patients with pneumonia admitted at Sichuan Provincial People’s Hospital was used as the validation group. The diagnostic performance of the nomogram was measured by area under the receiver-operating-characteristics curve (AUC), calibration curves, and the net benefit by decision curve. RESULTS: PJP prevalence was 25.3% in the development group. LASSO regression revealed that age, lymphocyte count, fever, dry cough, respiratory failure, ground-glass opacity in lungs, glucocorticoid therapy duration, and immunosuppressive therapy were indicators of PJP. The nomogram showed robust discrimination, with an AUC of 0.82 (95% CI 0.77–0.86) in the development group and an AUC of 0.87 (95% CI 0.80–0.94) in the validation group, both showing acceptable calibration. In the decision curve analysis, our model consistently achieved a greater net benefit across almost all ranges of clinical thresholds. CONCLUSION: We developed a nomogram with good diagnostic power for PJP diagnosis in pneumonia patients receiving oral glucocorticoids. This nomogram may help promote timely treatment of PJP and thus reduce the mortality rate in these patients.
format Online
Article
Text
id pubmed-9907006
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-99070062023-02-08 Development and Validation of a Diagnostic Nomogram for Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Pneumonia Patients Undergoing Oral Glucocorticoid Treatment Lang, Qin Li, Lijuan Zhang, Yue He, Xing Liu, Yafeng Liu, Zhen Yan, Haiying Infect Drug Resist Original Research PURPOSE: Pneumocystis jirovecii pneumonia (PJP) is an opportunistic but potentially fatal infection with increasing prevalence in HIV-free patients. Glucocorticoid therapy is one of the most important risk factors for PJP. The delay in diagnosis contributes to poor outcomes. Hence, the aim of this study was to develop and validate a nomogram for the diagnosis of PJP in patients with non-HIV-infected pneumonia who are undergoing oral glucocorticoid treatment. PATIENTS AND METHODS: This study was a retrospective, cross-sectional research. The development group included 434 patients who were admitted with pneumonia from 6 hospitals. Demographics, symptomatic features, laboratory and computed tomography data were analyzed using the least absolute shrinkage and selection operator (LASSO) to select potential diagnostic indicators. Binary logistic regression was used to develop a diagnostic nomogram. Another 119 patients with pneumonia admitted at Sichuan Provincial People’s Hospital was used as the validation group. The diagnostic performance of the nomogram was measured by area under the receiver-operating-characteristics curve (AUC), calibration curves, and the net benefit by decision curve. RESULTS: PJP prevalence was 25.3% in the development group. LASSO regression revealed that age, lymphocyte count, fever, dry cough, respiratory failure, ground-glass opacity in lungs, glucocorticoid therapy duration, and immunosuppressive therapy were indicators of PJP. The nomogram showed robust discrimination, with an AUC of 0.82 (95% CI 0.77–0.86) in the development group and an AUC of 0.87 (95% CI 0.80–0.94) in the validation group, both showing acceptable calibration. In the decision curve analysis, our model consistently achieved a greater net benefit across almost all ranges of clinical thresholds. CONCLUSION: We developed a nomogram with good diagnostic power for PJP diagnosis in pneumonia patients receiving oral glucocorticoids. This nomogram may help promote timely treatment of PJP and thus reduce the mortality rate in these patients. Dove 2023-02-04 /pmc/articles/PMC9907006/ /pubmed/36760781 http://dx.doi.org/10.2147/IDR.S398850 Text en © 2023 Lang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Lang, Qin
Li, Lijuan
Zhang, Yue
He, Xing
Liu, Yafeng
Liu, Zhen
Yan, Haiying
Development and Validation of a Diagnostic Nomogram for Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Pneumonia Patients Undergoing Oral Glucocorticoid Treatment
title Development and Validation of a Diagnostic Nomogram for Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Pneumonia Patients Undergoing Oral Glucocorticoid Treatment
title_full Development and Validation of a Diagnostic Nomogram for Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Pneumonia Patients Undergoing Oral Glucocorticoid Treatment
title_fullStr Development and Validation of a Diagnostic Nomogram for Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Pneumonia Patients Undergoing Oral Glucocorticoid Treatment
title_full_unstemmed Development and Validation of a Diagnostic Nomogram for Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Pneumonia Patients Undergoing Oral Glucocorticoid Treatment
title_short Development and Validation of a Diagnostic Nomogram for Pneumocystis jirovecii Pneumonia in Non-HIV-Infected Pneumonia Patients Undergoing Oral Glucocorticoid Treatment
title_sort development and validation of a diagnostic nomogram for pneumocystis jirovecii pneumonia in non-hiv-infected pneumonia patients undergoing oral glucocorticoid treatment
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907006/
https://www.ncbi.nlm.nih.gov/pubmed/36760781
http://dx.doi.org/10.2147/IDR.S398850
work_keys_str_mv AT langqin developmentandvalidationofadiagnosticnomogramforpneumocystisjiroveciipneumoniainnonhivinfectedpneumoniapatientsundergoingoralglucocorticoidtreatment
AT lilijuan developmentandvalidationofadiagnosticnomogramforpneumocystisjiroveciipneumoniainnonhivinfectedpneumoniapatientsundergoingoralglucocorticoidtreatment
AT zhangyue developmentandvalidationofadiagnosticnomogramforpneumocystisjiroveciipneumoniainnonhivinfectedpneumoniapatientsundergoingoralglucocorticoidtreatment
AT hexing developmentandvalidationofadiagnosticnomogramforpneumocystisjiroveciipneumoniainnonhivinfectedpneumoniapatientsundergoingoralglucocorticoidtreatment
AT liuyafeng developmentandvalidationofadiagnosticnomogramforpneumocystisjiroveciipneumoniainnonhivinfectedpneumoniapatientsundergoingoralglucocorticoidtreatment
AT liuzhen developmentandvalidationofadiagnosticnomogramforpneumocystisjiroveciipneumoniainnonhivinfectedpneumoniapatientsundergoingoralglucocorticoidtreatment
AT yanhaiying developmentandvalidationofadiagnosticnomogramforpneumocystisjiroveciipneumoniainnonhivinfectedpneumoniapatientsundergoingoralglucocorticoidtreatment